Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX was delisted on the 3rd of February, 2025.
102 hedge funds and large institutions have $316M invested in Viracta Therapeutics, Inc. Common Stock in 2014 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 41 increasing their positions, 28 reducing their positions, and 11 closing their positions.
157% more call options, than puts
Call options by funds: $10.9M | Put options by funds: $4.26M
64% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 11
46% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 28
7% more funds holding
Funds holding: 95 → 102 (+7)
0% less capital invested
Capital invested by funds: $317M → $316M (-$1.03M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$6.44M |
| 2 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
+$1.71M |
| 3 |
Stifel Financial
St. Louis,
Missouri
|
+$1.35M |
| 4 |
U
UBS
Zurich,
Switzerland
|
+$1.29M |
| 5 |
PCM
Palisade Capital Management
Fort Lee,
New Jersey
|
+$1.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$5.14M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.59M |
| 3 |
PC
PointState Capital
New York
|
-$2.31M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$1.28M |
| 5 |
EI
EAM Investors
Solana Beach,
California
|
-$1.07M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
BNP Paribas Financial Markets
Paris,
France
| $5.1K | +$1.16K | +1 | +33% |
|
102
Creative Planning
Overland Park,
Kansas
| $3K | +$2.32K | +2 | New |
|
|
SCA
103
SAC Capital Advisors
Stamford,
Connecticut
| – | -$3.32M | -2,395 | Closed |
|
|
PC
104
PointState Capital
New York
| – | -$2.31M | -1,667 | Closed |
|
|
SCM
105
Sigma Capital Management
Stamford,
Connecticut
| – | -$2.12M | -1,524 | Closed |
|
|
GPP
106
Great Point Partners
Greenwich,
Connecticut
| – | -$1.28M | -922 | Closed |
|
|
EI
107
EAM Investors
Solana Beach,
California
| – | -$1.07M | -773 | Closed |
|
|
HVC
108
Healthcare Value Capital
Woodcliff Lake,
New Jersey
| – | -$570K | -491 | Closed |
|
|
RFC
109
Russell Frank Company
Seattle,
Washington
| – | -$509K | -482 | Closed |
|
|
NCCM
110
Nine Chapters Capital Management
Short Hills,
New Jersey
| – | -$269K | -194 | Closed |
|
|
LP
111
LMR Partners
London,
United Kingdom
| – | -$219K | -158 | Closed |
|
112
SG Americas Securities
New York
| – | -$98K | -70 | Closed |
|
|
TRCT
113
Tower Research Capital (TRC)
New York
| – | -$5.8K | -5 | Closed |
|
VIRX Hedge Fund Activity: Q2 2014 in Review
102 of the 3,480 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q2 2014, worth a combined $316M — down 0.32% from $317M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new VIRX positions and 11 closed out — a net gain of 7 holders — while 41 added to existing stakes and 28 trimmed.
The largest buyer was Eagle Asset Management, opening a new position worth an estimated $6.44M. The largest seller was Farallon Capital Management, cutting an estimated $5.14M.
- 102 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q2 2014, up from 95 in Q1 2014.
- Funds reported $316M of Viracta Therapeutics, Inc. Common Stock stock for Q2 2014, down 0.32% quarter-over-quarter.
- 18 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q2 2014 and 11 closed out, a net change of +7 holders.
- The largest Viracta Therapeutics, Inc. Common Stock buyer in Q2 2014 was Eagle Asset Management, an estimated $6.44M added.
- The largest Viracta Therapeutics, Inc. Common Stock seller in Q2 2014 was Farallon Capital Management, an estimated $5.14M sold.
Based on aggregated 13F filings for Q2 2014.